Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.H. Lundbeck has reported positive results from a newly unblinded proof of concept clinical study with a compound for the treatment of major depressive disorder.
Subscribe to our email newsletter
The clinical trial was a multicenter, double-blind, placebo-controlled trial including 426 patients with major depression. According to the company, Lu AA21004 showed highly significant improvements on the primary efficacy endpoints with both 5 and 10mg compared to placebo and had an attractive safety profile.
Anders Gersel Pedersen, head of development at H. Lundbeck, said: “We are pleased that the encouraging results from this proof of concept study confirm our experimental expectations of Lu AA21004 as a potent and well-tolerated new drug for the treatment of major depression. Lu AA21004 is the most advanced project within the new bis-aryl-sulphanyl amine class of compounds for the treatment of mood disorders and anxiety, and we look forward to further exploiting the potential of these novel projects.”
Lu AA21004 is jointly being developed by H. Lundbeck and Takeda Pharmaceutical. Following analysis of the Phase II data, H. Lundbeck and Takeda will plan the next steps in the development of Lu AA21004.